Transform your Research with Advanced ctDNA Testing Solutions
Circulating tumor DNA (ctDNA) analysis continues to advance cancer research and treatment development. This non-invasive method enables the detection of tumor-derived DNA in blood and biofluids, offering critical research insights into tumor progression, therapy effectiveness, and recurrence. By investigating ways to more precisely measure molecular residual disease (MRD), also known as minimal residual disease or measurable residual disease, and monitor recurrence before symptoms reemerge, ctDNA testing has the potential to enable earlier interventions that lead to significantly improved outcomes.
The value of ctDNA analysis has gained recognition for clinical trials as the USFDA and other regulatory agencies develop guidance for using ctDNA biomarkers as potential endpoints. This capability facilitates faster patient enrollment, reduces costs, and streamlines the approval process, making it essential for the advancement of oncology research.
Start a Conversation with a Specialist
Did you know?
In 1948, Mandel and Metais discovered free DNA in the bloodstream, laying the groundwork for ctDNA testing. Its use in oncology began in earnest in the early 2000s, leading to breakthroughs in early cancer detection, tumor mutation profiling, and MRD monitoring.1
Featured Content
Overcome the Challenges of ctDNA Analysis with ddPCR Technology
Enhancing Sensitivity for Rare ctDNA Detection
ctDNA exists in trace amounts, particularly in low-shedding tumors, early-stage cancers, or after curative treatments. The QX600 ddPCR system provides high sensitivity and precision, enabling accurate detection and quantification of mutated DNA amidst abundant wild-type sequences in complex biofluids.
Targeting Multiple Biomarkers Simultaneously
Simultaneous quantification of multiple targets enhances the power of ctDNA analysis. The QX600 ddPCR system enables user-friendly multiplexing, simplifying lab logistics and minimizing required sample input while maintaining accuracy across numerous biomarkers.
Maintaining Reproducibility Across Studies
For research addressing therapy efficacy analysis, MRD detection, and recurrence monitoring, ddPCR platforms provide highly reproducible results across diverse samples and studies. The flagship QX600 ddPCR system ensures reliable, high-quality data, seamlessly integrating into your clinical oncology research applications.
Rapid, Cost-Effective ctDNA Testing in Clinical Research
The QX family of ddPCR platforms offer streamlined workflows, intuitive software, and expert support. The QX600 ddPCR system provides advanced multiplexing and simplified implementation, making it ideal for longitudinal studies, biomarker characterization, and clinical research.
Featured Content
When can you leverage ddPCR technology for ctDNA testing?
Unlock the full potential of ctDNA analysis with ddPCR—offering unmatched sensitivity, faster turnaround times, and cost-effective solutions. Designed for accuracy and efficiency, there is a best fit ddPCR method for every stage of the clinical research continuum, from MRD assessment to recurrence monitoring, ensuring precise and reliable results where they matter most.
Featured Content
Revolutionizing Clinical Research Through ctDNA Analysis
Therapy Response Analysis Research
Understanding and effectively optimizing therapeutic response analysis is vital for successful cancer treatment research. ctDNA testing delivers an innovative view of tumor dynamics, empowering researchers to evaluate treatment responses as they happen. This ensures you develop the most targeted and effective care possible.
Explore ddPCR SolutionsThe ddPCR Advantage
- Delivers early, actionable insights through precise ctDNA quantification, often before imaging detects changes
- Enables multiplex biomarker tracking to streamline workflows and preserve sample material
- Accelerates therapy evaluation in clinical research with a broad library of optimized assays
- Supports dynamic treatment adjustments to improve patient outcomes
MRD Detection Research
Understanding and effectively optimizing therapeutic response is vital for successful cancer treatment research. ctDNA testing delivers an innovative view of tumor dynamics, empowering researchers to evaluate treatment responses as they happen. This ensures you develop the most targeted and effective care possible.
See How ddPCR is Transforming MRD ResearchThe ddPCR Advantage
- Facilitates precise MRD detection in solid tumors and superior monitoring in hematologic malignancies
- Detects rare mutated DNA fragments among abundant wild-type sequences
- Streamlined workflows minimize hands-on time for efficient processing
- High precision and reproducibility support confident treatment assessment and large-scale studies
Recurrence Monitoring Research
Early detection of cancer recurrence plays a critical role in improving patient outcomes. Serial ctDNA quantification using highly sensitive ddPCR enables near real-time, non-invasive monitoring, often revealing molecular signs of relapse weeks or months before conventional imaging or clinical symptoms appear.
Learn More About ddPCRThe ddPCR Advantage
- Supports cost-effective, ultra-sensitive, same-day detection of mutation-specific ctDNA
- Streamlined workflow eliminates the need for complex bioinformatics
- Enables precise, serial monitoring for cancer recurrence research
- Advanced multiplexing on the QX600 platform delivers comprehensive insights across multiple targets
Harness the Power of Methylation Detection for Deeper Insights
DNA methylation plays a key role in cancer biology, influencing gene expression and tumor development. With ddPCR and methylation-sensitive restriction enzyme (MSRE) technologies, you can achieve ultra-sensitive, cost-effective methylation detection—unlocking critical epigenetic insights to advance your biomarker research.
Featured Resources
Groundbreaking MRD Breast Cancer Research
Explore how ctDNA analysis is transforming breast cancer care, predicting relapse early, and driving groundbreaking advances in oncology through innovation and perseverance.
Counting DNA Molecule by Molecule
Discover the transformative impact of ddPCR on nucleic acid quantification, from detecting rare variants to enhancing gene therapy and advancing clinical research.
Decisive moments In Precision Medicine are Revolutionizing Care
Uncover the power of ddPCR in advancing precision medicine. Monitor ctDNA to drive research covering non-invasively for treatment responses, resistance mutations, and relapse prediction with accuracy.
ctDNA Analysis Across the Cancer Research Continuum
Learn how ddPCR revolutionizes ctDNA analysis, delivering accurate, non-invasive biomarker detection to advance personalized cancer care and improve patient outcomes.
Featured Content
Discover Peer-Reviewed Research Empowered by Bio-Rad Solutions
Explore the ddPCR Publication Database
References
1 Mandel, P. and Métais, P. (1948) Les acides nucléiques du plasma sanguin chez l’Homme. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, 142, 241-243.
Featured Content
Explore Additional Oncology Solutions
Biomarker Detection
Transform biomarker research with ddPCR. Identify key mutations, track treatment response, and drive breakthroughs in precision medicine.
CTC Isolation & Analysis
Streamline CTC isolation with cutting-edge microfluidics and molecular tools. Enhance reproducibility and accelerate discoveries in liquid biopsy research.
Tumor Profiling
Optimize tumor profiling with advanced molecular tools. Detect rare mutations, analyze gene expression, and uncover biomarkers with confidence and precision.
IVD Assay Development
Optimize IVD assay development with ultra-sensitive ddPCR. Streamline workflows, reduce variability, and ensure compliance with global standards.